GLP-1 analogues are often given weekly, while MICC injections, NAD+ therapy, and GLOW Peptide Therapy protocols may be recommended weekly, biweekly, or in a specific treatment cycle based on your goals
Kamper M, Tsimpoukidi O, Chatzigeorgiou A, Lymberi M, Kamper EF
The DRI modification makes the peptide backbone unrecognizable to endogenous aminopeptidases, carboxypeptidases, and endopeptidases, extending functional persistence from minutes to an estimated hours-to-days range
It is recognized for promoting angiogenesis (new blood vessel growth) and reducing inflammation, which aids tissue repair
Preclinical models published in Obesity Research demonstrated that AOD-9604 administration increased lipolysis by 47% within 90 minutes of subcutaneous injection, with peak plasma concentrations occurring at 120 minutes post-dose